• FDA grants breakthrough therapy designation to GMI-1271 for AML

    5 monthes ago - By Healio

    The FDA granted breakthrough therapy designation to GMI-1271 for the treatment of adults with relapsed or refractory acute myeloid leukemia, according to the agent's manufacturer.GMI-1271 , a novel and proprietary E-selectin antagonist, is being evaluated in the phase 2 portion of an ongoing phase 1/phase 2 trial designed to assess the drug in combination with chemotherapy for patients with relapsed or refractory AML, and for patients aged 60 years or older with newly diagnosed disease.
    Read more ...